SET and breast carcinoma: Similarly, SET overexpression in patients with several solid tumor, including colorectal cancer [25], head and neck squamous cell carcinoma (HNSCC) [27], colorectal cancer, and breast cancer [28], shows promising therapeutic implications and determines poor clinical outcome.